Resources and News
FEATURED
Latest from Prescient
-
How did CI survive COVID-19? An analysis of how the CI function emerged from the depths of a pandemic
-
How can you maximize value amid shifting tides in pharmaceutical new product planning? Dr. Conrad Tenenbaum Director Debbie Allman Senior Vice President Dr. Debasish...
In our white paper, “Trends and Challenges in Pharmaceutical New Product Planning: The Cornerstone of Value Creation”, we piece together the puzzle of pharmaceutical value creation in an ever-changing world 🧩. Read more: https://hubs.ly/Q023H1JG0
Five years! Congratulations, Ankur Chhalotre
Resources & News
Filter Categories
All
Event
Blog Post
White Paper
Case Study
Press Release
In The News
-
How did CI survive COVID-19? An analysis of how the CI function emerged from the depths of a pandemic
-
How can you maximize value amid shifting tides in pharmaceutical new product planning? Dr. Conrad Tenenbaum Director Debbie Allman Senior Vice President Dr. Debasish...
-
This year's Pharma CI USA Conference will be held on September 20-21, 2023, in Newark, NJ. This is the largest...
-
Advanced combination treatment (ACT) combines biologic agents and/or oral small molecule drugs. The opportunity for ACT in inflammatory bowel...
-
Prescient Healthcare Group supported Incyte Biosciences Iberia in executing ImPATH (IMprove PATient PATHway in DLBCL), a project that engaged...
-
On April 26, 2023, the European Commission (EC) published two major legislative proposals that lay the groundwork for the...
-
Here at Prescient, we’re excited to share a major step in our sustainability journey. After careful calculation of our...
-
Planning for the complexities of regulatory nuances with appropriate internal investment sets the foundation for a successful EAP strategy
-
We are thrilled to announce that Strategic North, part of Prescient Healthcare Group, won the ‘Best Customer Insight Approach’...
-
Strategic North, part of Prescient Healthcare Group, has been highly commended and selected as finalists in a few categories...
-
Gretzky did not do it all himself, and neither should you.
-
How Did We Get Here and What Happens Next?
-
Dr. Erica Carlisle, Dr. Paul Harney and Swati Anand Kkatyal join the Prescient Board of Directors, bringing years of...
-
The Healthcare Businesswomen’s Association (HBA) is set to honor outstanding women in leadership at its annual Woman of the...
-
Will Sanofi and Takeda rise to the challenge?
-
At Prescient, we are pleased to announce that we have joined the United Nations Global Compact, a voluntary leadership...
-
Identifying sustainable success in a highly dynamic, emerging market
-
Vault Firsthand has published its industry rankings for 2023 based on the results of the 2022 EMEA and North...
-
What should developers consider to ensure both market success and the greatest public good?
-
RLT is a targeted therapy with the potential to treat oncology patient populations with high unmet needs, but how...
-
The Pharma CI Europe 2023 Conference will be held on March 30-31, 2023, in Rome, Italy.
-
We are proud to announce that Katy Chun has been recognized as a Healthcare Businesswomen’s Association (HBA) 2023 Rising...
-
Prescient hires three new senior members to support its growing Medical Center of Excellence.
-
Diane Whelan, Head of Learning and Development at Prescient, will present at the 23rd People Development Summit in Sitges,...
-
Our colleague Sabina Zikmundova held an EU-funded workshop on menstruation and female health for youth workers in Georgia to...
-
In partnership with MAPS, Prescient will moderate a webinar on Friday, January 27, 2023, at 10:00 AM EDT.
-
Jamie Denison-Pender moves into corporate development role as Dr. Debasish Talukdar becomes the new Chief Executive Officer.
-
Deep-dive into the evolving JAK Paradigm with special focus on topicals
-
How to deliver winning brand propositions that can pay huge dividends
-
Now in its fourth year, Prescient’s research study on strategic imperatives in CI collects feedback from thought leaders across...
-
The Pharma CI USA 2022 Conference will be held September 21-22, 2022, in Newark, US.
-
The Prescient Academy creates a culture of lifelong learning and development that enables Prescient team members to grow their...
-
How did CI survive COVID-19? An analysis of how the CI function emerged from the depths of a pandemic
-
The current late-stage pipeline is driving intense competition for patient share
-
Physicians and Pharma need to understand why this fast-developing technology will transform routine screening and modernize the adjuvant setting
-
Prescient hires two new senior members and opens an office in Barcelona.
-
This blog looks at the critical success factors of a ‘good’ LCM plan and the learnings from success stories...
-
PLOS Medicine has published an article by Prescient’s Ivan Zhelyazkov.
-
With the improvement of MM treatments, physicians and healthcare providers must respond to the new needs of long-term survivors.
-
We are pleased to announce that Strategic North is a finalist in the Best Patient-Centric Approach category for the...
-
The MAPS EMEA 2022 Annual Meeting will be held May 15-17, 2022, Paris, France.
-
In this white paper, Prescient sets out a roadmap for Medical Affairs launch excellence strategy to boost a product’s...
-
The 2022 Healthcare Businesswomen’s Association Woman of the Year Luncheon will be held on May 10 at the New...
-
We are delighted to announce that Jeanne Penn is being recognized as a 2022 HBA Luminary Award winner. Jeanne...
-
Prescient announces the recent acquisition of Strategic North, a global commercial strategy consultancy that partners with a wide range...
-
The 2022 Biocom Global Life Sciences Partnering Conference will be held from February 22 to 24, 2022 in San...
-
Prescient announces the recent appointments of Shirin Ahmed, Dr. Erica Carlisle and Dr. Christian Wasmer as leaders in the...
-
Highly competitive markets require different thinking for an asset to succeed. As landscapes expand to more players and evolve...
-
China represents huge opportunities – and risks. Prescient has gathered thought leaders for a roundtable discussion on the approaches...
-
The European market has opportunities, but the wrong approach could leave value on the table. Prescient’s guide will steer...
-
Prescient grows its global footprint in Europe with the opening of locations in Munich and Madrid.
-
The third annual white paper on the strategic imperatives in CI is out now. Competitive intelligence (CI) is fundamental...
-
COVID-19 has revolutionized the use of sophisticated technologies in drug development
-
Pharma has been slow to fully utilize technology in processes and decision-making. The swift development of COVID-19 vaccinations has...
-
Non-medical switching (NMS) seems attractive on paper but often leads to poor clinical outcomes and higher overall costs to...
-
Medical Affairs (MA) is a “sleeping giant” with potential to offer companies significant strategic value. While MA has occasionally...
-
Nature has accepted and published research by Prescient’s Amol Padgaonkar.
-
Competitive Intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug...
-
Prescient hires Gerald Dunstan as Chief Strategy Officer to execute the company’s growth strategy.
-
Our Prescient spirit is built on pride and passion for science, intellectual curiosity, and a joint commitment to achievement....
-
Prescient’s Anna Graca has published an article in GLIA.
-
Prescient’s Anuj Gupta has published an article in Economic Times.
-
A webinar exploring the potential for CI practitioners to boost their businesses and careers
-
Early insights on emerging trends in Europe for 2021-2022.
-
Prescient’s Andrea Campi’s doctoral research has yielded a published article in Bone.
-
The slow uptake of biosimilars in the US market may have lulled some into a false belief that they...
-
Prescient hires two new senior members to expand its expertise and keep pace with the company’s growth.
-
Pharma leaders need to understand the factors holding assets back from reaching full potential and keep a sense of...
-
The Journal of Health Policy and Economics has accepted and published research from Prescient’s Marselia Tan.
-
While all global biopharma has had to respond to COVID, UK domiciled biopharma is also faced with the long-term...
-
In this first of two blogs Nick Turner, Senior Director at Prescient Healthcare Group looks at how COVID is...
-
Prescient announces the recent appointment of two new senior members: Emma Leung and Matt Majer.
-
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by loss of cognitive function (specifically memory loss) and inability to...
-
The unmet need in AML continues to be quite high despite the advances in cancer research.
-
Prescient announces the recent appointment of two new senior members: Emma Leung and Matt Majer.
-
Prescient Healthcare Group has been recognized, for the fourth year in a row, as one of the 50 fastest-growing...
-
Innovative brands need to revisit their biosimilar plans to ensure they can maximize their time over the competition
-
Most of the therapeutic candidates target rare diseases and cancers which are difficult to treat and do not have...
-
Cell Chemical Biology has accepted and published research from Prescient’s Syed Meheboob Ahmed:
-
The slowdown of recent growth in the Chinese Pharma market demonstrates potential for western companies to partner with their...
-
Digital health can speed the identification and approval of agents in oncology, rare diseases, immunology and neurology.
-
Prescient Healthcare Group announced today that Bridgepoint Development Capital, part of Bridgepoint, the international alternative asset management group, has...
-
As ADCs continue to get incorporated in the treatment landscape across several solid tumors, data emerging from the next...
-
Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore...
-
The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Nature has accepted and published a manuscript from Prescient’s Aakriti Verma in their “Scientific Reports”. This research revealed novel...
-
Last year, Prescient embarked upon the ambitious exercise of interviewing competitive intelligence (CI) practitioners across the pharmaceutical industry to...
-
Prescient hires three new senior members to expand its expertise and keep pace with the company's growth. Gordon Gochenauer,...
-
How you spend your CI budget is as important as how much you are spending; therefore, it is vital...
-
Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug...
-
In this white paper, Ben Doran and Jeanne Penn draw on their experiences in the pharmaceutical field to explain...
-
Among the available cancer treatments, pembrolizumab is an industry bellwether: A drug that is as close to a “silver...
-
October 21, 2020, marks the Carnegie Council’s Global Ethics Day, but as far as Prescient is concerned, every day...
-
New product planning fails more often than it succeeds. Prescient’s Global Head of Advisory looks at why this happens...
-
The 2020 Annual Ph.D. to Consulting (PTC) Conference will be a virtual event held on September 25, 2020.
-
In partnership with Biocom, Prescient will present a webinar on October 22 to October 27 at 11:00 AM PDT.
-
The 2020 Baird Global Healthcare Conference will be held virtually on September 9-10, 2020.
-
Prescient will be attending the virtual 2020 Pharma CI USA Conference and Exhibition on September 29-October 1, 2020.
-
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has...
-
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has...
-
In our previous blog, COVID’s impact on the Pharma industry, we highlighted the major macroeconomic factors that are shaping...
-
The COVID-19 pandemic poses the greatest public health emergency for 100 years, coupling high infectivity with a case mortality...
-
Prescient announces the recent appointment of two new senior members, Peter Donachie and Dr. Haroon Khan, to its Advisory...
-
Prescient announces the recent appointment of three new senior members to its Intelligence & Insight business: Dr. Anuj Gupta,...
-
Pharma in the post-COVID era – adapting to the new normal is the latest whitepaper from Prescient, providing a...
-
Now more than ever, we are facing the question of why we need digital media monitoring (DMM). Competitors are...
-
In partnership with Biocom, Prescient will be presenting a webinar on Wednesday, August 8 at 1:00 PM PT.
-
Prescient’s thought leaders address major shifts in the landscape and outline near-, medium- and long-term choices facing pharma strategy...
-
The impact of COVID-19 on clinical and regulatory affairs, manufacturing and supply chains, and stakeholder engagements has slowed the...
-
Regulatory agencies across the world are issuing flexible guidelines to cater to the COVID-19 public health emergency. This is...
-
Content and offerings are evolving – so should your approach to maximize insights.
-
Charles Darwin would have been fascinated to sit back and observe how our society evolves to cope with the...
-
Do you feel that without a physical congress, you are losing an essential tool in understanding the dynamics of...
-
The continued rise of COVID-19 is expected to have short- and long-term impacts across the key biopharmaceutical functions, and...
-
Prescient Healthcare Group has been recognized, for the third year in a row, as one of the 50 fastest-growing...
-
Prescient’s Dr. Julia Seaman shares her thoughts on monitoring COVID-19 in the American Society for Quality’s March issue of...
-
Prescient is proud to share the exciting news that we will be officially opening a Boston office!
-
Prescient will be in Zurich for the 2020 Pharma CI Europe Conference and Exhibition on March 19-20, 2020.On Thursday,...
-
Prescient announces the recent appointment of two new senior members, Kevin Baruzzi and Dr. Arun Shrivats, to its Advisory...
-
Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its...
-
The 2020 Biocom Global Life Sciences Partnering Conference will be held from February 25 to 27, 2020 in La...
-
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in...
-
Prescient’s Andrea Campi’s doctoral research has yielded a published manuscript in Connective Tissue Research: Mechanosensitive Ca2+ signaling and coordination is...
-
Too Big to Ignore: What CI Needs to Do to Make the China Market Manageable Chinese pharmaceutical companies present both...
-
The American Society of Gene and Cell Therapy has accepted and published a manuscript from Prescient’s Carly Jones in...
-
LeadingBiotech’s East/West CEO will be held during January 11-12, 2020, in San Francisco. The event brings together global leaders...
-
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market...
-
Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response...
-
Prescient’s Andrea Campi has been recognized with the ASBMR Young Investigator Award. The American Society for Bone and Mineral Research...
-
The 2019 annual Pharma CiMi.CON will be held on November 7-8 in Boston. Dr. Mark Little will attend this...
-
Prescient will be in Boston, MA, for the 2019 New Product Planning Summit on December 2-3, 2019. On December 2...
-
The Biocom Q4 2019 Deal Makers Reception Awards will be held on Thursday, December 12, in La Jolla, California....
-
The 2019 FierceBiotech Drug Development Forum will be held on October 28-29, 2019, in Boston. Dr. Mark Little will...
-
The European Society of Cardiology has accepted and published a manuscript from Prescient's Carly Jones in Cardiovascular Research: A novel...
-
The 2019 Annual Ph.D. to Consulting (PTC) Conference will be held on September 20, 2019, in London. The conference...
-
The 2019 Baird Global Healthcare Conference will be held on September 4-5, 2019, in New York. Dr. Paul Harney...
-
The Institute for the Study of Business Markets (ISBM)'s Driving Marketing Excellence and Strategic Insights for B2B event will...
-
Prescient will be in Newark, NJ, for the 2019 Pharma CI USA Conference and Exhibition on September 18-19, 2019. On...
-
Skin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among...
-
The BIO International Convention will be held June 3-6, in Philadelphia, PA. The event attracts 16,000+ biotechnology and pharma...
-
LeadingBiotech's Boston CEO will be held on May 28-29. The event brings together past, present and future leaders in...
-
ExL Events’ Medical Affairs Strategic Summit (MASS) will be held April 24-26 in Morristown, NJ. The event addresses the...
-
LeadingBiotech's Cancer Advance Boston will be held on April 24. The event brings together past, present and future leaders...
-
Featuring quotes from EMEA President, Dr. Rakesh Verma In this article by Consultancy.uk, Dr. Rakesh Verma discusses how we advise...
-
Prescient Healthcare Group has been recognized, for the second year in a row, as one of the 50 fastest-growing...
-
Sidnee Pinho, Prescient's US Chief Operating Officer, led a workshop at Rutgers University on February 1, 2019. Sidnee Pinho began the...
-
The 2019 Spring MedAffairs Leaders Forum will be held February 26-28, 2019, in London. This event brings together senior decision-makers...
-
The 2019 Biocom Global Life Science Partnering Conference will be held February 26-28, 2019, in La Jolla. The event...
-
Prescient will be in Basel for the 2019 Pharma CI Europe Conference and Exhibition on March 5-6, 2019. On March...
-
LeadingBiotech's East/West CEO will be held January 5-6, 2019, in San Francisco. The event brings together global leaders in...
-
Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases...
-
Lung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small...
-
The Biocom Q4 2018 Deal Makers Reception Awards will be held on Thursday, December 13, in La Jolla, California....
-
The CLSA 15th Annual Pantheon 2018 – Presenting DiNA™ Awards will be held on Friday, November 30, 2018, in...
-
Prescient will be in Boston, MA for the 2018 New Product Planning (NPP) Summit on December 12-13, 2018. On December...
-
Breast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018....
-
With regulatory approval, CAR-T cell therapy must address significant unmet needs in clinical practice without restrictions in order to...
-
The 18th Annual Biotech in Europe Forum, organized by Sachs Associates, will be held October 4-5, 2018, in Basel, Switzerland....
-
Featuring quotes from Dr. Paul Harney, President – North America, and Ben Druck, Principal. In this article by Medical Marketing...
-
A largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier...
-
The 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies, organized by Hanson Wade, will...
-
The Baird's 2018 Global Healthcare Conference will be held September 5-6, 2018, in New York. Dr. Paul Harney and...
-
Prescient will be in Newark, NJ for the 2018 Pharma CI USA Conference and Exhibition on September 26-27, 2018. On...
-
Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under...
-
Our global pharmaceutical client had a product whose patent was expiring within a year. The client wanted to understand...
-
Our client, a European specialty pharmaceutical company, was considering an expansion of indications within its target therapeutic group via...
-
Prescient Healthcare Group, a biopharmaceutical product and portfolio strategy firm, announces the recent appointment of Dr. Paul Harney as...
-
Ben Doran has been recognized for the "40 Under 40 in Cancer" Award. This award celebrates the contributions of young oncology professionals...
-
Access to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to...
-
Prescient is committed to respecting our clients’ privacy and personal data. Over the past few months, we have audited...
-
Featuring quotes by Dr. Rakesh Verma, President, EMEA & APAC Big pharma companies are increasingly reliant on consultants to communicate...
-
Our global pharmaceutical client was developing a suite of biosimilars that it intended to commercialize in several Latin American...
-
By: Tanya Casimiro, PhDAs the first Phase III data in non-alcoholic steatohepatitis (NASH) begin to be released, the next...
-
Prescient will be in London for the 2018 SMi Annual Pain Therapeutics Conference on May 21-23, 2018. On May 23,...
-
There is significant interest in companion diagnostics (CDx) throughout the healthcare industry, but for this personalized medicine approach to...
-
Approximately 7,000 rare diseases affect more than 300 million people worldwide, or around 5-8% of the population, depending on...
-
On April 16, 2018, data from multiple pivotal trials in first-line (1L) non-small-cell lung cancer (NSCLC) were presented at...
-
Our client, a global pharmaceutical company, was in the process of strengthening the vision for its future product portfolio.
-
Our global pharmaceutical client’s mature product was two years away from patent expiry in its key regulated markets and...
-
The US healthcare system has been facing great uncertainty, with ongoing challenges to the sustainability of the Affordable Care...
-
Prescient Healthcare Group has been recognized as one of the 50 fastest-growing companies in 2017. We have been ranked...
-
Prescient Healthcare Group, a global product strategy and decision support consultancy, announces the recent appointment of Dr. Debasish Talukdar...
-
Our client, a global pharmaceutical company, sought to decide whether to progress two internal assets into Phase III development...
-
Quotes by: Jamie Denison-Pender, CEO, Prescient. Jamie provides Prescient’s views of the industry and market conditions. This report brings together...
-
Prescient will be in Lisbon, Portugal for the 2018 Pharma CI Europe Conference and Exhibition on February 27-28. Joanne Taylor,...
-
Prescient Healthcare Group, a global product strategy and decision support consultancy, announces the recent appointments of Nick Edwards and...
-
Our client, a global pharmaceutical company, planned to launch a new product about six months ahead of a direct...
-
Our client, a global pharmaceutical company, wanted to devise a global strategy to proactively address threats from the launch...
-
Our client, a global pharmaceutical company, needed to identify opportunities in the EU5 countries for a first-in-class injectable product...
-
Our client, a global specialty pharmaceutical company, was seeking to evaluate the clinical and commercial attractiveness of a potential...
-
Baird’s 10th annual Global Healthcare Conference was held in New York on September 6-7, 2017 and featured nearly 100...
-
Prescient will be in Dusseldorf, Germany for the 2017 Pharma Market Research Conference (PMRC) Europe on October 24-25, 2017....
-
Our client was developing a novel cellular therapy with promising Phase I safety data and some evidence of efficacy...
-
Our client, a global pharmaceutical company, was planning to launch its first-ever biosimilar for the treatment of inflammatory conditions.
-
Our global pharmaceutical client needed a long-term partner who could deliver evidence-based insights to support the clinical, commercial and...
-
Baird Capital, the direct investment arm of Robert W. Baird & Co., announced today that it has acquired an...
-
Our global pharmaceutical client had an immunotherapy in early-stage clinical development.
-
Our global pharmaceutical client needed to prioritize launch regions for a biosimilar in a large and growing therapeutic area...
-
Our client, a global pharmaceutical company, had a drug in development for a disease area dominated by high-efficacy drugs...
-
Our client, a global pharmaceutical company, was planning to launch a second-in-class biologic in a crowded market space.
-
Our global pharmaceutical client needed insights into the then-unknown biosimilars space and assistance in successfully defending its franchises.
-
Our global pharmaceutical client’s drug had one of the most successful launches in its category and monopolized the market...
-
Due to the increase in incidence of a particular disease worldwide, our client, a global pharmaceutical company, wanted to...
-
Our client, a global pharmaceutical company, was planning to launch an immunology agent.
-
Our client, a global pharmaceutical company, had a biologic in development for the treatment of a condition with a...
-
Years of non-small cell lung cancer (NSCLC) research are beginning to result in significant gains in the standard of...
-
Prescient assessed opportunities across patient segments to guide our client’s go-to-market strategies.
-
Prescient developed a five-year forecast of potential cellular therapy patients to guide our client’s treatment center qualification strategy.
-
Prescient conducted a situational analysis of the immunology market to identify high-impact trends and evolving HCP prescribing behaviors to...
-
Prescient helped accelerate, assure and simplify the client’s annual medical affairs strategic planning across its solid tumor franchise.
-
Prescient conducted an in-depth analysis of competitor global medical affairs teams to understand best practices in the industry.
-
Prescient developed a BD assessment framework to identify attractive candidates in an oncology indication with a high unmet need.